MDMA Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Pharmala Biotech Holdings Inc

Watchlist Manager

Watchlist

Price: 0.245 CAD Market Closed

Market Cap: CA$26.6m

P	Pharmala Biotech Holdings Inc CNSX:MDMA	CA

Profitability Summary

Pharmala Biotech Holdings Inc's profitability score is 11/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

89%

Strong 3Y Average Gross Margin

96%

Gross Margin is Increasing

85% > 89%

Negative Operating Margin

-181%

Negative 3Y Average Operating Margin

-226%

Declining Operating Margin

-147% > -181%

Negative Net Margin

-184%

Negative 3Y Average Net Margin

-235%

Declining Net Margin

-147% > -184%

Negative Free Cash Flow Margin

-108%

Negative 3Y Average Free Cash Flow Margin

-132%

Free Cash Flow Margin is Increasing

-159% > -108%

Negative ROE

-62%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-68%

Declining ROIC

-57% > -78%

View All

Hide

Collapse

11 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.